Thermogenesis closes $2.05 million public offering

Rancho cordova, calif. , oct. 28, 2022 /prnewswire/ -- thermogenesis holdings, inc. (nasdaq: thmo) (the "company"), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the closing of its previously announced public offering of 11,783,572 shares of its common stock, $0.001 par value (the "common shares"), 2,892,858 pre-funded warrants to purchase common shares, and warrants to purchase up to an aggregate 14,676,430 common shares at an offering price to the public of $0.14 per share and associated warrant, for aggregate gross proceeds of approximately $2.05 million excluding the proceeds, if any, from the exercise of the warrants.
THMO Ratings Summary
THMO Quant Ranking